The underlying defect is, in almost 90% of the molecular diagnosed FH patients, a mutated low-density lipoprotein receptor (LDLR), which results in a more than doubling of the plasma low-density lipoprotein cholesterol (LDL-C) levels. This evidence concerns the gene LDLR and familial hyperaldosteronism.